Vizient’s private label spans more than 14,000 line items. The antitrust case that ended on October 5 never examined it.

Vizient's Novaplus private label spans more than 14,000 line items across 130 contracts. The antitrust case that ended on October 5 was told the label competes with the suppliers Vizient puts on contract, and no court examined whether it does.

This piece asks five questions and answers each from the public record. The allegations described are Endure's and no court has ruled on the merits of any of them. GPO Intel's own inferences are labelled "Our read" wherever they appear, and are opinion.

1. What did the courts decline to examine?
2. What was decided, and when?
3. What did Endure actually allege?
4. Why did the case fail, and what did that failure decide?
5. What does the opinion establish about Vizient?

What did the courts decline to examine?

The Fifth Circuit ended its opinion by naming three things it was not going to reach: "We elect not to address the remaining issues, such as Vizient's alleged competition through its NovaPlus private label, exclusive dealing, and market foreclosure," under the rule that it "will not reach the merits of an issue not considered by the district court." (5th Cir. No. 24-10995, at 18, quoting PHH Mortg., 80 F.4th at 563.)

The first of those is worth sizing. Vizient's own product page describes Novaplus, which it spells without the interior capital the court used, as a private label offering "more than 14,000+ line items to reduce costs and ensure supply resilience," and counts "100 + Suppliers," "130 + Contracts" and "180M + Buffer units" through its Enhanced Supply programs. The brand "encompasses a broad range of categories needed across the care continuum, including anesthesia, business products and services, diagnostic imaging, food, laboratory, medical, orthopedic, pediatric, pharmacy, respiratory, and surgical." (vizient.com, Novaplus product page, read on October 16, 2026.)

Our read: the plaintiff here is a relabeler, and the thing it says competes with it is the defendant's own relabel. The court described Endure as commissioning supplies from overseas manufacturers and selling them under its own name, which is the same business Novaplus is in at 14,000 line items and 130 contracts, across categories that include the medical and surgical goods Endure sold. Whether that is ordinary competition or something else is the question nobody has answered: it was raised, the district court did not reach it, and the Fifth Circuit declined to take it up first. For a supplier on a Vizient contract that is the live issue in this case, and it is the part that ended unexamined.

What was decided, and when?

Endure Industries, Incorporated sells disposable medical supplies. The Fifth Circuit describes it as "a 'relabeler' or 'repackager,' commissioning DMS from manufacturers overseas and then selling directly to health care providers." (5th Cir. No. 24-10995, at 3.) Endure bid to join Vizient's group purchasing program as a supplier of medical tape, and the court records that "Vizient rejected that bid in favor of 3M." (Id.)

Endure sued in 2020 in the Northern District of Texas, case 3:20-CV-3190. (5th Cir. No. 24-10995, at 1.) The defendants are Vizient, Incorporated, Vizient Supply, L.L.C., Vizient Source, L.L.C., and Provista, Incorporated, which the opinion refers to collectively as "Vizient." (Id. at 2.)

That fourth defendant is the one most of our readers deal with. Provista describes itself as "a leader in group purchasing, applies the collective buying power of members to deliver best-in-class sourcing and analytic services across multiple industries," serving non-acute healthcare alongside business and hospitality buyers. (provista.com, read on October 16, 2026.)

Our read: the court did not treat the four defendants as separate companies with separate conduct. It collapsed them into a single definition and analysed them as one, which means every mechanic described below, the rebate thresholds and the fee structure both, was litigated with Provista inside that definition. For a non-acute buyer who reaches these contracts through Provista, that is the practical point: the arrangement the court examined is the one they are in.

On October 9, 2024 the district court granted summary judgment. Vizient had moved on three grounds, and the opinion records that "the court ruled on only the first issue," which was whether Endure's proposed antitrust markets were legally sufficient. (5th Cir. No. 24-10995, at 4.) On January 13, 2026 a Fifth Circuit panel of Judges Smith, Stewart and Ramirez affirmed, in an opinion by Judge Jerry E. Smith whose first line sets the scope: "This appeal is about market definition under antitrust law." (5th Cir. No. 24-10995, at 1.) Its last: "Endure has failed to satisfy its burden to establish a genuine dispute of material fact as to either of its proposed antitrust markets. The summary judgment is AFFIRMED." (Id. at 19.) The Supreme Court denied certiorari on October 5, 2026. (No. 25-1385, Order List of October 5, 2026, under CERTIORARI DENIED.)

At the Supreme Court the docket runs short. Endure got an extension to May 13 from Justice Alito and filed that day, together with a motion to file the petition under seal with redacted copies for the public record, which was granted on June 15. (No. 25-1385, docket entries of April 2, April 9, May 13 and June 15, 2026.) The sealed material is sealed and this piece says nothing about its contents. Vizient waived its right to respond on June 22, and the docket contains no entry requesting one. (Docket entry of June 22, 2026.) The case went to the September 28 conference, the first of the term, with one amicus brief filed by Elizabeth H. Rader. (Docket entries of June 24 and July 16, 2026.)

Our read: a denial of certiorari sets no precedent and states no view of the merits, and this docket shows a petition the respondent did not answer and the Court did not ask it to answer. We record those as facts and draw nothing from them about either party's view of the case.

Our read: six years, two federal courts and a cert petition produced no ruling on whether anything Vizient does is lawful. That is unusual enough to be the story. A case can be fully litigated and fully lost without the conduct at its center ever being examined.

What did Endure actually allege?

The opinion states the claims in these words: Endure brought "an antitrust complaint in 2020 against Vizient, alleging monopolization by exclusive dealing with bid-rigging, unilateral refusal to deal, essential facilities monopolization, and vertical rebate agreements in restraint of trade in two proposed markets for medical products." (5th Cir. No. 24-10995, at 4.) Those are allegations and none was adjudicated.

The mechanism Endure pointed to was the rebate program. Vizient's Impact Standardization Program pays rebates to members who concentrate enough of their buying inside one of thirteen product bundles. A member projects its annual spend across the bundle, and the opinion quotes an internal document saying that projection "should cover a member's entire spend in the category with all suppliers." (5th Cir. No. 24-10995, at 3.) To collect: "The GPO member must then meet 90% compliance for each individual SKU to receive a rebate for that product, as well as 75% overall compliance to receive any rebates across that ISP bundle. Vizient monitors compliance with the category-spend obligations on a quarterly basis." (Id.)

Endure's case was that Vizient's incentive programs "effectively lock in Member Hospitals to purchasing [disposable medical supplies] exclusively through Vizient," and that members "cannot afford to forego [sic] purchasing . . . [disposable medical supplies] through Vizient because it is cost-prohibitive for Member Hospitals to switch to a new GPO." (Endure's allegations, as characterized in the opinion: 5th Cir. No. 24-10995, at 16.)

Our read: the allegation was never that a contract forbids a member from leaving. It was that the economics make leaving expensive. That distinction set the evidentiary question the case then turned on, and it is why the answer below is narrower than it first looks.

Why did the case fail, and what did that failure decide?

On the first proposed market, the district court faulted Endure's expert "for failing to account for the fact that only 72% of U.S. hospital purchases ran through GPOs, such that Endure had left out nearly 30% of the relevant market, which the court called, 'powerful evidence of the alternatives reasonably available to customers.'" (5th Cir. No. 24-10995, at 5.) It also noted that of the 629 GAC hospitals that had left Vizient, 174 "abandoned the GPO model entirely (27.6%)." (Id.)

On the second, the court found "no allegations suggest [Vizient] members are prevented from buying the supplies they need outside a GPO, joining and purchasing through additional GPOs, or leaving the GPO altogether." (5th Cir. No. 24-10995, at 5.) And then the sentence that decides the case: "Endure also does not adduce or trace specific facts related to high costs of switching to other GPOs—which would be probative of lock-in—as is required to resist summary judgment." (Id. at 18.)

The Fifth Circuit affirmed on that ground and went no further, declining the three remaining issues quoted at the top of this piece. (Id. at 18.)

What does the opinion establish about Vizient?

A published federal appellate decision makes figures citable that are otherwise almost impossible to source about a private group purchasing organization. These are the court's statements of the record before it, each in the construct the court used.

On scale, Vizient "is the largest Group Purchasing Organization ('GPO') in the country, controlling 53% of market share," and "is also the largest GPO focused on GACs, serving over 50% of acute-care health systems and 97% of academic medical centers." (5th Cir. No. 24-10995, at 2.) Separately, and in a different construct, it "captures more than 53% of net patient revenue in the GPO market, and its contract portfolio aggregates more than $140 billion in demand, including at least $7 billion in the GAC market." (Id. at 3.) Market share and share of net patient revenue are different measurements; the opinion gives 53% for each and this piece does not merge them.

On structure: "Historically, the GPO market contained twelve national purchasing member organizations in 1997 along with several regional and local GPOs, but today has consolidated to three national GPOs and several local GPOs accounting for 2.5% or less of the market." (5th Cir. No. 24-10995, at 3.)

On fees, the court writes that Vizient "charges fees to its members called Contract Administrative Fees ('CAFs'), which vary depending on the number of Vizient-brokered contracts the member assumes, and may be prorated down if the member participates in Vizient's ISP rebate program." (5th Cir. No. 24-10995, at 2-3.) The opinion states no rate.

Our read: the two numbers that decided this case, 72% of hospital purchases running through GPOs and 27.6% of departing hospitals leaving the model entirely, are the two least quoted figures in it. They are also the ones a supplier should care about, because they are the court's measure of how much buying sits outside the channel Endure said was the only way in.

---

*Method. Drawn from the published opinion of the United States Court of Appeals for the Fifth Circuit in No. 24-10995, decided January 13, 2026 on appeal from N.D. Tex. No. 3:20-CV-3190, and from the Supreme Court's public docket and order list in No. 25-1385, both read on October 13, 2026. Provista's self-description and the Novaplus figures are from the companies' own sites, read on October 16, 2026. Every quotation is verbatim from the document cited beside it.*